Structural Biology

The Stetefeld lab performs a hybrid method approach by combining several 3D structural biology techniques. The focus is on the acquisition of high-resolution data in conjunction with time-scale dynamics.  

Infrastructure available:

• Facility for insect- and mammalian cell expression and HP-Fermenter system

• PCR’s and a Next Generation Sequencer

• Crystallisation facility

• Crystal Microspectrophotometer for trace fluorescent labeling

• TALOS F200C (equipped with a Falcon 4 DED)

• X-ray Diffractometer

• 600MHz NMR instrumentation

Long-term beamtime proposals at the Canadian Light Source (CLS), Advanced Photon Source (APS) and DIAMOND (UK) guarantee access to high-brilliance and microfocus beamlines at several synchrotrons and the performance of SEC-SAXS experiments.

Biophysics

The Stetefeld lab established a unique combination of in-depth biophysical characterization of hydrodynamic properties in combination of different scattering techniques in synergy with analytical ultracentrifugation. Microscale thermophoresis and Bio-layer Interferometry together with interferometric scattering mass spectrometry is ideally suited for the exploration of the dynamic behavior of high-molecular weight protein complexes and for unraveling molecular insights of receptor-ligand formation at near physiological conditions. Since 2021, we are a partner lab for NANOTEMPER and can perform state-of-the-art nano-DSF-DLS experiments.

Infrastructure available:

• FPLC-JASCO (FSEC), SEC-MALS-RI and SEC-MALS-QUELS instrumentation

• Dynamic Light Scattering (DLS)

•Analytical Ultracentrifuge (AUC)

•Microscale Thermophoresis (MST)/ nano-DSF-DLS (PANTA)

•ForteBio Octet K2

•interferometric Scattering Mass Spectrometry (iSCAMS)

Molecular Modelling

In a variety of different projects, the Stetefeld lab applied several in silico modeling and structure-based Molecular Dynamics simulations to guide enhanced diagnosis and therapeutic approaches in the field of extracellular signaling complexes. Most recently, in collaboration with ATOMWISE, AI-driven approaches for structure-based drug design were applied.